people who delay hepatitis C treatment remain at risk for liver failure,
hepatocellular carcinoma and liver-related death even after being cured – with
outcomes worsening the longer it is put off – indicating that treatment should
not be deferred until advanced disease, according to a presentation at the 2015
Conference on Retroviruses and Opportunistic Infections (CROI) last week in
Seattle. Treating only after progression to cirrhosis increased the risk of
liver-related death by more than five-fold and the duration of infectiousness
Over years or decades chronic hepatitis C virus (HCV) infection can lead
to advanced liver disease including cirrhosis (scarring), hepatocellular
carcinoma (HCC; a type of primary liver cancer) and end-stage liver failure.
People with HIV/HCV coinfection experience faster disease progression, on
average, than those with HCV alone. Successful hepatitis C treatment reduces -
but does not eliminate - the risk.
Labels: CROI 2015, deferring treatment, Disease Progression, Long term outcomes